Outlook Therapeutics FY2025 net loss $62.4M; $1.4M revenue from LYTENAVA launch in Europe

Outlook Therapeutics, Inc.

Net loss $62.4M ($1.79/share) vs $75.4M ($4.06/share) prior year; revenue $1.4M from initial EU sales.
Cash $8.1M at Sept 30, 2025; $14.9M net from ATM after quarter-end; no debt mentioned.
Expenses fell $4.6M YoY due to lower R&D, partly offset by higher SG&A for European launch.
FDA PDUFA goal date for ONS-5010 is Dec 31, 2025; awaiting U.S. approval decision.
LYTENAVA accepted into UK tender framework in Dec 2025; launch expanding to Austria and Netherlands.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.